PITTSBURGH. (KFSN) -- About 400,000 Americans are living with multiple sclerosis. Ten thousand new cases are diagnosed every year. MS is a disease of the central nervous system. Among other things, it ...

The second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis reported positive interim results with 70% of patients not requiring a third course of treatment. The second ...

We remind investors that in Dec 2013, the FDA had issued a complete response letter (CRL) for Lemtrada mentioning that there was not enough evidence from adequate and well-controlled studies to show ...

The FDA mentioned in the CRL that there is not enough evidence from adequate and well-controlled studies that Lemtrada possesses a positive benefit-risk profile. The FDA has asked Sanofi to conduct ...

The review comes following new reports of immune-mediated conditions. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of Sanofi’s multiple ...

Sanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters. Thursday, the agency put out a notice citing “rare but serious” ...

A new treatment for multiple sclerosis (MS) recently received a thumbs down from the FDA, citing the need for additional testing. The trials reviewed for MS drug Lemtrada (alemtuzumab) need to provide ...

Before long, she had constant pins and needles, was unable to pick up a cup or cradle her son, and she knew she had to find out what was going on. “My GP told me I might have carpel tunnel syndrome, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Patients with relapsing remitting multiple sclerosis who received Sanofi’s Lemtrada ® (alemtuzumab) continued to experience effects of treatment on disease activity ...

Genzyme announced that select patients in the United States are the first to have initiated treatment for relapsing forms of multiple sclerosis (MS) with Lemtrada (alemtuzumab) injection through the ...

Sanofi has been battling claims that it dragged its feet on multiple sclerosis (MS) drug candidate Lemtrada, acquired in its Genzyme buyout, to avoid follow-up payments to investors. But now, the ...

PARIS --Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion ...